

can." The authors of the report concluded that the report also addresses a number of benefits of software beyond the economic, including self-confidence and convenience. In addition, the new report contains a focus on ways in which pharmaceutical manufacturers can be optimized, including through the uptake of good practices using "standard operating procedures for quality management of software should be developed," they further concluded.

3D Printing Applications in Transforming Medical Devices and Pharma Industries, Fosters Frost & Sullivan's Industry View

FROST & SULLIVAN (NASDAQ: FROST) announced today that its research and advisory services division has released a new report titled "3D Printing Applications in Transforming Medical Devices and Pharma Industries." The report highlights the potential of 3D printing technology in the pharmaceutical industry, from the efficient production of complex and personalized products. A large number of medical devices have already been produced using 3D printing, for its ability to customize drugs, Active Pharmaceutical Ingredients (APIs) and medical devices, among an array of personalized medicines. The full list of areas likely to be disrupted by 3D printing is a primary objective of drug leaders of the use of 3D printing customized drug production of medicine.

"Using 3D printed custom for drug testing, clinical trials and medical testing will have a huge impact on the pharma sector as this will help decrease costly animal testing and use of multiple doses," informed Frost & Sullivan (F&S) Research Analyst, Millennium Program, in a press note. "However, traditional large scale manufacturing is still more economical for mass production of drugs. 3D printing will be viable for small volume production to replace them," he further added.

3D printing for healthcare applications, come from F&S's Healthcare Medical Devices & Imaging Council. Personalized services program, that has been a a drive with a pharma sector (Continuous Manufacturing (CM), which can make production time to less than 24 hours. When this process is merged with 3D printing, pharma companies can develop custom drugs faster for a specific, customized demographic. 3D printing will also bring about a change in the structure of the medicine, making it easier to swallow or breathe, and more attractive to children by printing them in an shape of fun.

Currently, the most researched and popular route for the development of drugs / medicines using 3D printing technology are Personalized medicine, which can be used with patient based medicines. The other / pills manufactured can be customized to the patient's requirements by extracting their level of liver, with precise dosage of each ingredient, in a granule form. The use of 3D printing technology in druging and prototyping will also immediately reduce clinical testing.

Despite all the progress being made, the pharma industry is facing challenges in manufacturing personalized medicines. Regulatory bodies for medical applications of 3D printing. Furthermore, there are high chances of counterfeiting in the

market. "Current products being developed using 3D printing are largely in application areas such as medical implants, surgical guides, prosthetics, orthodontics, and customized models for surgery," added the analyst. Furthermore, a number of opportunities is opening up in future healthcare applications such as in creation of bone structures, drug delivery method options and medicines," concluded he further in the note.

Nigeria Pharma Manufacturers' Expo 2017 to Explore Untapped Potential of African Pharma Markets



LAGOS: The fourth edition of Nigeria Pharma Manufacturers' Expo (NPME) 2017, recognized as one of the biggest international pharmaceutical manufacturing technologies exhibition for the Central and West African region, is slated to take place from August 30 to September 01, 2017 at Ikeja, Lagos, Nigeria. NPME 2017 is being jointly organized by the Pharmaceutical Manufacturers Group of Manufacturers' Association of Nigeria (PMG-MAN), an umbrella body of Nigerian manufacturers of medicines & healthcare products; and GPE Expo Pvt. Ltd., an India-based event organizer. PharmaNEWS and Pharma Pro&Pack trade publications are the official media partners, while www.NigeriaPharmaExpo.com is its official website.

The main objective of the Expo would be an opportunity for stakeholders in the health sector to exchange information, products, services and ideas towards achieving health-related Millennium Development Goals (MDG) and other developmental initiatives in Nigeria and West African region. "The event will attract more than 150 exhibiting companies and nearly 3,800 pharma trade professionals from across the region including Benin, Burkina Faso, Cameroon, Central African Republic, Chad, EQ Guinea, Gambia, Ghana, Ivory Coast, Mali, Niger, Nigeria, Senegal, among others," said the organizers in a press note.

According to the organizers, "Online registration for trade visitors has already started and can be done instantly from the official website." Added the note, "The pharma professionals from Nigeria and its neighbouring countries have already started getting registered online as visitors for the expo."

The focused industry segments of the expo are pharmaceuticals, cosmetics, nutraceuticals, veterinary, beverages and distilleries. These segments have current growth rate of 14-15% per annum in Nigeria. In fact, Nigeria has the largest number of pharma manufacturing units amongst entire West African region.

Health Systems and Pharmacies Must be Prepared for Challenges of Precision Medicine, Says GlobalVantage Institute

GLOBALVANTAGE, a new report from GlobalVantage Institute outlines a number of challenges that health systems need to address in order to maximize the benefits the precision medicine offer to patients. Precision medicine are defined as treatments tailored to groups of patients based on predictive biomarkers which indicate who is likely to benefit from the drug or to individuals based on their unique genetic profile or